Multiple Myeloma

Treatment Considerations for Transplant-Ineligible Patients with MM

Nausheen Ahmed, MD, and Al-Ola Abdallah, MD, discuss the use of CAR T-cell therapy in patients with transplant-ineligible multiple myeloma.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Relapsed/Refractory Multiple Myeloma: Incidence of CRS in MajesTEC-1

The expert panel gives an overview of factors that influence treatment decisions in patients with transplant-ineligible multiple myeloma.

Thomas G. Martin, MD;Ajay K. Nooka, MD;Jeremy Larsen, MD

Unmet Needs and Future Directions in the Management of Multiple Myeloma

Focused discussion on the advent of cytokine release syndrome in MajesTEC-1 and how it compared to the benefits derived from teclistamab therapy.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Long-Term Followup With Talquetamab in Relapsed/Refractory MM: Infection Rates

Experts from Ochsner Health close out their panel on multiple myeloma management by identifying unmet needs and sharing excitement for future evolution in the treatment landscape.

Practical Considerations for Talquetamab Use in Relapsed/Refractory Multiple Myeloma

July 13th 2023

Expert hematologist-oncologists identify long-term data from MonumenTAL-1 regarding infection rates in patients with relapsed/refractory multiple myeloma.

Community Care Provider’s Perspective on Administering Bispecifics in Patients with MM

July 13th 2023

Following their review of data from MonumenTAL-1, Ajai Chari, MD, and Carolina Schinke, MD, share practical considerations for real-world use of talquetamab in relapsed/refractory multiple myeloma.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

July 11th 2023

Focused discussion on how patients receiving bispecific therapy for multiple myeloma are transitioned into and managed within the community setting.

Bispecifics in Multiple Myeloma: Transitioning Patient Care to the Community Setting

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

July 11th 2023

Expert panelists share insight on transitioning patients on bispecific therapy from an academic or specialty center to the community setting.

Discussing Bispecific Antibody Treatment With Patients With Multiple Myeloma

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 10th 2023

Catherine Wei, MD, and David Witt, MD, explain some of the reasons they would recommend treatment with bispecific antibodies to their patients with multiple myeloma.

Application of Bispecific Therapy in Clinical Practice

Natalia Neparidze, MD;Noffar Bar, MD;Elan Gorshein, DO, JD, MPH;Catherine Wei, MD;David Witt, MD;Syed S. Ali, MD

July 10th 2023

Syed S. Ali, MD, and Noffar Bar, MD, share their practical experience with bispecific antibodies in the treatment of patients with multiple myeloma.

Experts on multiple myeloma discuss how to select treatment options in later lines of therapy.

Relapsed/Refractory Multiple Myeloma: Factors in Selecting Later-Line Therapy

Thomas G. Martin, MD;Ajay K. Nooka, MD;Jeremy Larsen, MD

MAIA Trial: DRd vs Rd in Transplant-Ineligible Patients with MM

Experts on multiple myeloma discuss how to select treatment options in later lines of therapy.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Patient Profile 2: A 79-Year-Old with Multiple Myeloma

Leyla O. Shune, MD, reviews the MAIA trial, which looked at DRd vs Rd in patients with transplant-ineligible multiple myeloma.

Al-Ola Abdallah, MD;Leyla O. Shune, MD;Nausheen Ahmed, MD;Jordan Snyder, PharmD

Role of CAR T-cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

The expert panel presents the case of a patient with multiple myeloma and discusses evaluating transplant eligibility in patients with MM.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Unmet Needs and Future Perspectives in Multiple Myeloma

Before closing out their module on relapsed/refractory multiple myeloma, key opinion leaders reflect on the role of CAR T-cell therapy and patient access to care.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Relapsed/Refractory Multiple Myeloma: Managing Patients on Bispecific Therapy

A panel of experts discuss unmet needs in multiple myeloma and offer perspectives on the future treatment landscape.

Andrew P. Dalovisio, MD;Kelly Pippin, MD;Ryan P. Griffin, MD;Ernest C. Quintin, MD;Thomas Atkinson, MD

Bispecific Antibodies vs CAR T-Cell Therapy in Multiple Myeloma

Centering discussion on bispecific therapy, panelists consider dosing strategies and adverse event management in relapsed/refractory multiple myeloma.

C. Ola Landgren, MD, PhD;Dickran Kazandjian, MD;Benjamin Diamond, MD;Dennis Verducci, APRN

Relapsed/Refractory MM: Safety and Efficacy Data From MonumenTAL-1

An expert panel compares bispecific antibodies with CAR T-cell therapy and discusses treatment sequencing.

MonumenTAL-1 in Relapsed/Refractory MM: Overview of Study Design

July 6th 2023

Focused discussion on the safety and efficacy data from MonumenTAL-1, which utilized talquetamab monotherapy in patients with relapsed/refractory multiple myeloma.

Key Takeaways from Health Care Systems on the Role of Bispecifics in MM

July 6th 2023

Following a brief review of the relapsed/refractory multiple myeloma treatment landscape, Carolina Schinke, MD, provides an overview of the MonumenTAL-1 study design.

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

July 5th 2023

The panel closes their discussion by highlighting crucial takeaways about the use of bispecific antibodies in the treatment of multiple myeloma.

Future Perspectives on the Role of Bispecifics in MM

Binod Dhakal, MD, MS;Joseph R. Mikhael, MD;Cindy Varga, MD;Beth Faiman, PhD, CNP;Jeremy Larsen, MD

July 5th 2023

Doctors discuss the potential of bispecific therapies being used in earlier lines of treatment for multiple myeloma, and the need for understanding and reducing toxicities as much as possible.

Closing Thoughts on Bispecific Antibodies and the Future of R/R MM Treatment

Surbhi Sidana, MD;Melissa Alsina, MD; Maria-Victoria Mateos, MD, PhD;Jack Khouri, MD

July 5th 2023

The panel looks to the future of relapsed/refractory multiple myeloma treatment and the remaining unmet needs for patients.

The standard of care for high-risk multiple myeloma remains unsettled, according to an expert panel from Kansas City.

Experts Spotlight Some of The ‘Biggest Concerns’ In Multiple Myeloma

Al-Ola Abdallah, MD;Nausheen Ahmed, MD;Leyla O. Shune, MD;Jordan Snyder, PharmD

Bispecifics in MM: Future Directions in Care

The standard of care for high-risk multiple myeloma remains unsettled, according to an expert panel from Kansas City.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Long-Term Monitoring for CRS and AEs With Bispecific Therapy

Closing out their panel on bispecifics in relapsed/refractory multiple myeloma, key opinion leaders share closing thoughts and hopes for the future treatment landscape.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP

Selecting Patients for BCMA and Non-BCMA Bispecifics in Multiple Myeloma

Long-term considerations for the detection and treatment of CRS and other adverse events when managing patients with multiple myeloma.

Rafael Fonseca, MD;Shaji Kumar, MD, Mayo Clinic;Joselle Cook, MBBS, Mayo Clinic;Morie A. Gertz, MD, MACP, Mayo Clinic

Initial Monitoring for CRS and AEs in Patients With MM on Bispecifics

Expert panelists from Mayo Clinic discuss their approach for the use of BCMA and non-BCMA targeting bispecifics, respectively, in patients with relapsed/refractory multiple myeloma.

Cesar Rodriguez, MD;Scott A. Soefje, PharmD;Kirollos S. Hanna, PharmD, BCPS, BCOP, FACCC;Frances A. Bell, NP